“Essential” phospholipids versus nicotinic acid in the treatment of patients with type IIb hyperlipoproteinemia and ischemic heart disease

Autor: Klimov, Anatoli N., Konstantinov, Vladimir O., Lipovetsky, Boris M., Kuznetsov, Alexander S., Lozovsky, Vladimir T., Trufanov, Vladimir F., Plavinsky, Svjatoslav L., Gundermann, Karl-Josef, Schumacher, Rainer
Zdroj: Cardiovascular Drugs and Therapy; December 1995, Vol. 9 Issue: 6 p779-784, 6p
Abstrakt: In patients with moderate, dietary noncorrigible hyperlipoproteinemia type IIb and ischemic heart disease, treatment with nicotinic acid is limited by the side effects of the drug. In 100 patients, 6-month treatment with nicotinic acid (n=50) or “essential” phospholipids (EPL); Lipostabil®, manufacturer: Rhône-Poulenc Rorer) (n=50) indicated comparable efficacy for both substances: Significant (p<.001) reductions of serum total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride values were similar in both groups, while nicotinic acid increased high-density lipoprotein (HDL) cholesterol significantly (p<.01) better than Lipostabil. A detailed analysis of ultracentrifugal lipoprotein profiles, hydroperoxide concentrations in LDL, and cholesterol-accepting properties of HDL in a small number of Lipostabil- and nicotinic acid-treated patients revealed favorable shifts in the lipoprotein profile, significant (p<.05) reductions of LDL hydroperoxides, and favorable increases of the most antiatherogenic HDL2b subfraction only in the Lipostabil-treated group. Clinically, both medications reduced the intensity and number of angina pectoris attacks per week (p<.05), but only Lipostabil-treated patients significantly (p<.05) increased their working capacity in the veloergometric test. Since in the nicotinic acid-treated group dropouts (nine patients, eight related to the drug) and side effects [14] exceeded those in the Lipostabil-treated group (two dropouts not related to the drug, no side effects), it is suggested that Lipostabil is a preferable alternative in the treatment of patients with moderate, dietary noncorrigible hyperlipoproteinemia IIb and ischemic heart disease.
Databáze: Supplemental Index
Externí odkaz: